Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  BRCA2 mutation carrier
Stage/Subtype:  BRCA2 mutation carrier
Trial Status:  Active
Results 1-25 of 75 for your search:
Start Over
National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations
Phase: Phase IV
Type: Screening
Status: Active
Age: 25 to 70
Sponsor: Other
Protocol IDs: DBCG07MRBRCA, NCT00413491
Fenretinide in Healthy Young Women at Genetic and Familial Risk
Phase: Phase III
Type: Prevention
Status: Active
Age: 20 to 46
Sponsor: Other
Protocol IDs: IEO S462/109, 2009-010260-41, NCT01479192
Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-001687, NCT01591746
High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: N12OLG, 2012-000838-19, NCT01646034
Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Approved-not yet active
Age: 25 to 55
Sponsor: NCI, Other
Protocol IDs: A211102, U10CA031946, NCI-2013-00995, NCT01905046
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PR-30-5010-C, 1307-BCG, BIG5-13, NCT01905592
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 673-301, U1111-1155-7579, NCT01945775
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D0819C00003, 2013-005137-20, NCT02000622
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D081CC00006, BIG 6-13, NSABP B-55, NCT02032823
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-914, 2014-000345-70, NCT02163694
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D081FC00001, 2014-001589-85, NCT02184195
Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: PLAN14001, NCT02240199
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2015-00606, NRG-GY004, U10CA180868, NCT02446600
Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer
Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 90
Sponsor: Other
Protocol IDs: 102/07 (HT4351), NCT00496288
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 21 to 49
Sponsor: Other
Protocol IDs: 12377, NCT01276704
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-895, 2011-002913-12, NCT01506609
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00864, CDR0000732189, MSKCC-12-045, 12-045, 8993, N01CM00032, N01CM00071, P30CA008748, U01CA069856, UM1CA186705, NCT01585805
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MITO15, NCT01772979
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 673-201, NCT02034916
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCI 2013-01-03, NCI-2014-02412, N01-CN-2012-00035, HHSN2612201200035I, NWU2013-01-03, R43CA091483, P30CA060553, N01CN00035, NCT02314156
Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03458, CDR0000710900, DFCI-11-144, 11-144, 8484, P30CA006516, R01CA090687, U01CA062490, UM1CA186709, NCT01434316
Trial of Olaparib in Combination With AZD5363 (ComPAKT)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CCR4058, 2013-004692-13, NCT02338622
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14955, NCT02358200
Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BGB-290-AU-002, NCT02361723
Start Over